Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.

Abstract

BACKGROUND\nRadiotherapy (RT) following breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) reduces ipsilateral breast event rates in clinical trials. This study assessed the impact of DCIS treatment on a 20-year risk of ipsilateral DCIS (iDCIS) and ipsilateral invasive breast cancer (iIBC) in a population-based cohort.\n\n\nMETHODS\nThe cohort comprised all women diagnosed with DCIS in the Netherlands during 1989-2004 with follow-up until 2017. Cumulative incidence of iDCIS and iIBC following BCS and BCS\u2009+\u2009RT were assessed. Associations of DCIS treatment with iDCIS and iIBC risk were estimated in multivariable Cox models.\n\n\nRESULTS\nThe 20-year cumulative incidence of any ipsilateral breast event was 30.6% (95% confidence interval (CI): 28.9-32.6) after BCS compared to 18.2% (95% CI 16.3-20.3) following BCS\u2009\u2009+\u2009\u2009RT. Women treated with BCS compared to BCS\u2009+\u2009RT had higher risk of developing iDCIS and iIBC within 5 years after DCIS diagnosis (for iDCIS: hazard ratio (HR)age\u2009<\u200950 3.2 (95% CI 1.6-6.6); HRage\u2009≥\u200950 3.6 (95% CI 2.6-4.8) and for iIBC: HRage<50 2.1 (95% CI 1.4-3.2); HRage\u2009≥\u200950 4.3 (95% CI 3.0-6.0)). After 10 years, the risk of iDCIS and iIBC no longer differed for BCS versus BCS\u2009+\u2009RT (for iDCIS: HRage\u2009<\u200950 0.7 (95% CI 0.3-1.5); HRage\u2009≥\u200950 0.7 (95% CI 0.4-1.3) and for iIBC: HRage\u2009<\u200950 0.6 (95% CI 0.4-0.9); HRage\u2009≥\u200950 1.2 (95% CI 0.9-1.6)).\n\n\nCONCLUSION\nRT is associated with lower iDCIS and iIBC risk up to 10 years after BCS, but this effect wanes thereafter.